Abstract 685: GPC2 is an oncogene and immunotherapeutic target in high-risk neuroblastoma
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-685
Abstract: Background: GD2-directed immunotherapeutic strategies have improved outcomes in neuroblastoma; however, the majority of patients treated suffer relapse and GD2 expression on pain fibers causes dose-limiting toxicities. Methods: To identify alternative cell surface immunotherapeutic targets, we… read more here.
Keywords: immunotherapeutic target; oncogene immunotherapeutic; high risk; gpc2 oncogene ... See more keywords